- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04506073
Phase IIa Randomized Placebo Controlled Trial: Mesenchymal Stem Cells as a Disease-modifying Therapy for iPD
November 28, 2023 updated by: Mya Schiess, The University of Texas Health Science Center, Houston
A Randomized, Double-blind, Placebo-controlled Trial of Allogeneic Bone Marrow-derived Mesenchymal Stem Cells as a Disease-modifying Therapy for Idiopathic Parkinson's Disease
The purpose of this study is to select the safest and most effective number of repeat doses of allogeneic bone marrow-derived mesenchymal stem cell (MSC) infusions to slow the progression of Parkinson's disease (PD).
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Single site phase IIa study of allogeneic MSC in a double blind randomized control trial as disease modifying therapy for PD.
The design includes three treatment arms with 45 patients.
Study Type
Interventional
Enrollment (Actual)
45
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Texas
-
Houston, Texas, United States, 77030
- The University of Texas Health Science Center at Houston
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
50 years to 79 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Diagnosis of Parkinson's disease by the UK brain bank criteria including the presence of 2 cardinal signs of PD plus bradykinesia.
- Mild microsomia to anosmia.
- A modified Hoehn and Yahr stage of 3 or less.
- Date of diagnosis of PD between 3 to 10 years
- Robust response to dopaminergic therapy.
Exclusion Criteria:
- Atypical, vascular, or drug-induced Parkinsonism.
- An atypical DAT scan or MRI supporting an alternative explanation for PD symptoms.
- Patient not on levodopa containing medications.
- Clinical features of psychosis or refractory hallucinations.
- A Montreal Cognitive Assessment (MoCA) score of less than 25.
- Uncontrolled seizure disorder.
- Abnormal Kidney and liver function.
- Presence of clinically refractory orthostatic hypotension at the screening or baseline visit.
- Body mass index of greater than or equal to 35.
- Cardiac disease: History of congestive heart failure, clinically significant bradycardia, presence of 2nd, or 3rd-degree atrioventricular block.
- Pulmonary disease: COPD with oxygen-requirement at rest or with ambulation; or moderate to severe asthma.
- Active malignancy or diagnosis of malignancy within 5 years prior to the start of screening
- Any current suicidal ideation or behaviors.
- Any diagnosis of autoimmune disease or immunocompromised state
- History of medium or large size vessel cerebrovascular accidents.
- History of traumatic brain injury with loss of consciousness and residual neurologic symptoms.
- Major surgery within the previous 3 months or planned in the ensuing 6 months.
- History of use of an investigational drug within 90 days prior to the screening visit.
- History of brain surgery for PD.
- Substance abuse disorder.
- Active anticoagulation treatment and/or abnormal INR.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: MSC+placebo
2 treatment doses + 1 placebo 3 months apart
|
2 infusions of 10 X 10^6 MSC/kg and 1 placebo every 3 months.
Other Names:
|
Experimental: MSC
3 treatment doses 3 months apart
|
3 infusions of 10 X 10^6 MSC/kg every 3 months.
Other Names:
|
Placebo Comparator: Placebo
3 placebo doses 3 months apart
|
3 infusions of placebo every 3 months.
Placebo will be identical to the investigational product but will not contain MSCs.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Safest number of effective doses of MSC as measured by the Part III of the Movement Disorder Society Unified Parkinson's disease Rating Scale (MDS-UPDRS) scale
Time Frame: Screening
|
Screening
|
Safest number of effective doses of MSC as measured by the Part III of the Movement Disorder Society Unified Parkinson's disease Rating Scale (MDS-UPDRS) scale
Time Frame: Week 7, post infusion #1
|
Week 7, post infusion #1
|
Safest number of effective doses of MSC as measured by the Part III of the Movement Disorder Society Unified Parkinson's disease Rating Scale (MDS-UPDRS) scale
Time Frame: Week 20, post infusion #2
|
Week 20, post infusion #2
|
Safest number of effective doses of MSC as measured by the Part III of the Movement Disorder Society Unified Parkinson's disease Rating Scale (MDS-UPDRS) scale
Time Frame: Week 29, post-infusion #3
|
Week 29, post-infusion #3
|
Safest number of effective doses of MSC as measured by the Part III of the Movement Disorder Society Unified Parkinson's disease Rating Scale (MDS-UPDRS) scale
Time Frame: Week 39 follow-up
|
Week 39 follow-up
|
Safest number of effective doses of MSC as measured by the Part III of the Movement Disorder Society Unified Parkinson's disease Rating Scale (MDS-UPDRS) scale
Time Frame: Week 52 follow-up
|
Week 52 follow-up
|
Safest number of effective doses of MSC as measured by the Part III of the Movement Disorder Society Unified Parkinson's disease Rating Scale (MDS-UPDRS) scale
Time Frame: Week 78 follow-up
|
Week 78 follow-up
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety and tolerability as measured by serious adverse reactions.
Time Frame: Baseline,week 7,week 20,week 29,week 39,week 78
|
Baseline,week 7,week 20,week 29,week 39,week 78
|
|
Safety and tolerability as measured by immunologic responses.
Time Frame: Baseline,week 7,week 20,week 29,week 39,week 78
|
Donor specific antibodies (DSA) in serum of patients will be measured and compared to baseline to determine if there is a development of antibody response to donor HLA (human leukocyte antigen).
This will determine if there is a possibility of anti-donor alloimmune response after the first or second infusion of MSC, which might lead to a subsequent antibody-mediated rejection (AMR) with the following infusion.
Testing will be done at the these time points to determine if 2nd or 3rd infusions will continue.
|
Baseline,week 7,week 20,week 29,week 39,week 78
|
Motor function as measured by the Timed-Up-and-Go (TUG) scale
Time Frame: Baseline,week 7,week 20,week 29,week 39,week 52,week 78
|
This test uses the time that a person takes to rise from a chair, walk three meters, turn around, walk back to the chair, and sit down.
A longer duration of time indicates a worse outcome
|
Baseline,week 7,week 20,week 29,week 39,week 52,week 78
|
Global measurement of disability as measured by the change in the screening "Off" modified Hoehn and Yahr (H&Y)
Time Frame: Baseline,week 7,week 20,week 29,week 39,week 52,week 78
|
Baseline,week 7,week 20,week 29,week 39,week 52,week 78
|
|
Quality of life as measured by the modified Schwab and England activities of daily living scale (ADL)
Time Frame: Baseline,week 7,week 20,week 29,week 39,week 52,week 78
|
Baseline,week 7,week 20,week 29,week 39,week 52,week 78
|
|
Quality of life as measured by the Parkinson's Disease Questionnaire 39 (PDQ-39)
Time Frame: Baseline,week 7,week 20,week 29,week 39,week 52,week 78
|
Baseline,week 7,week 20,week 29,week 39,week 52,week 78
|
|
Quality of life as measured by the EuroQol- 5 Dimension (EQ-5D)
Time Frame: Baseline,week 7,week 20,week 29,week 39,week 52,week 78
|
Baseline,week 7,week 20,week 29,week 39,week 52,week 78
|
|
Non-motor symtoms as measured by the The University of Pennsylvania Smell Identification Test (UPSIT- 40 odor test booklet).
Time Frame: Baseline,week 29,week 78
|
Baseline,week 29,week 78
|
|
Cognitive function as measured by the the change in Montreal Cognitive Assessment (MoCA)
Time Frame: Baseline,week 29,week 78
|
Baseline,week 29,week 78
|
|
Behavioral changes as measured by the Columbia Suicide Severity Rating Scale (C-SSRS)
Time Frame: Baseline,week 7,week 20,week 29,week 39,week 52,week 78
|
The Columbia-Suicide Severity Rating Scale (C-SSRS) is an assessment tool that evaluates suicidal ideation and behavior.
It rates an individual's degree of suicidal ideation on a scale, ranging from "wish to be dead" to "active suicidal ideation with specific plan and intent".
Exclusionary criteria views 1 or more positive answers in the last month as not eligible for participation.
In follow up, one positive response requires further investigation.
|
Baseline,week 7,week 20,week 29,week 39,week 52,week 78
|
Behavioral changes as measured by the Geriatric Depression Scale-Short Form (GDS-SF)
Time Frame: Baseline,week 7,week 20,week 29,week 39,week 52,week 78
|
The Geriatric Depression Scale Short form (GDS-SF) is a 15-item screening tool that is used to identify depression in older adults.
Answers indicating depression are in bold and italicized; score one point for each bold one selected.
A score of 0 to 5 is normal.
A score greater than 5 suggests depression and requires evaluation, whereas a score of 10 or greater would require evaluation for treatment .
|
Baseline,week 7,week 20,week 29,week 39,week 52,week 78
|
Behavioral changes as measured by the Parkinson Anxiety Scale (PAS)
Time Frame: Baseline,week 7,week 20,week 29,week 39,week 52,week 78
|
Baseline,week 7,week 20,week 29,week 39,week 52,week 78
|
|
Measurement of putative paracrine mechanism of MSCs using neuroimaging
Time Frame: Baseline,week 29,week 78
|
Baseline,week 29,week 78
|
|
Measurement of putative paracrine mechanism of MSCs as measured by concentration of cytokines in patient blood sample.
Time Frame: Baseline,week 7,week 20,week 29,week 39,week 78
|
Examples of these are IL-1beta, IL-6, TNF-alpha, COX-2 and PGE-2.
These are measured by Magnetic Bead Panel - Multiplex Assay or ELISA, allowing for specificity in the blood.
|
Baseline,week 7,week 20,week 29,week 39,week 78
|
Measurement of putative paracrine mechanism of MSCs as measured by concentration of chemokines in patient blood sample.
Time Frame: Baseline,week 7,week 20,week 29,week 39,week 78
|
Examples of these are CCL2 (MCP-1), CCL7 (MCP-3), CCL11 (Eotaxin) CCL2 (MDC), CXCL10 (IP-10), CX3CL1 (Fractalkine).
These will be measured by Magnetic Bead Panel - Multiplex Assay or ELISA, allowing for specificity in the blood.
|
Baseline,week 7,week 20,week 29,week 39,week 78
|
Measurement of putative paracrine mechanism of MSCs as measured by concentration of growth factors
Time Frame: Baseline,week 7,week 20,week 29,week 39,week 78
|
Examples of these are Glial Derived Neurotrophic Factor, Brain Derived Neurotrophic Factor and Vascular Epidermal Growth Factor .
These will be measured by ELISA specific to blood and CSF.
|
Baseline,week 7,week 20,week 29,week 39,week 78
|
Measurement of putative paracrine mechanism of MSCs as measured by concentration of neurotransmitters
Time Frame: Baseline,week 7,week 20,week 29,week 39,week 78
|
Examples of these are homovanillic acid and 5-hydroxytryptamine.
These will be measured in CSF and blood by ELISA.
|
Baseline,week 7,week 20,week 29,week 39,week 78
|
Measurement of putative paracrine mechanism of MSCs as measured by alpha-synuclein oligomers in the blood (serum or plasma)
Time Frame: Basleline,week 29,week 39,week 78
|
Basleline,week 29,week 39,week 78
|
|
Measurement of putative paracrine mechanism of MSCs as measured by alpha-synuclein oligomers in the cerebral spinal fluid
Time Frame: Baseline,week 39
|
Baseline,week 39
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Principal Investigator: Mya C Schiess, MD, The University of Texas Health Science Center, Houston
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Dorsey ER, Sherer T, Okun MS, Bloem BR. The Emerging Evidence of the Parkinson Pandemic. J Parkinsons Dis. 2018;8(s1):S3-S8. doi: 10.3233/JPD-181474.
- Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging. 2003 Mar-Apr;24(2):197-211. doi: 10.1016/s0197-4580(02)00065-9.
- Connolly BS, Lang AE. Pharmacological treatment of Parkinson disease: a review. JAMA. 2014 Apr 23-30;311(16):1670-83. doi: 10.1001/jama.2014.3654.
- Jellinger KA. Basic mechanisms of neurodegeneration: a critical update. J Cell Mol Med. 2010 Mar;14(3):457-87. doi: 10.1111/j.1582-4934.2010.01010.x. Epub 2010 Jan 11.
- Kortekaas R, Leenders KL, van Oostrom JC, Vaalburg W, Bart J, Willemsen AT, Hendrikse NH. Blood-brain barrier dysfunction in parkinsonian midbrain in vivo. Ann Neurol. 2005 Feb;57(2):176-9. doi: 10.1002/ana.20369.
- Gray MT, Woulfe JM. Striatal blood-brain barrier permeability in Parkinson's disease. J Cereb Blood Flow Metab. 2015 May;35(5):747-50. doi: 10.1038/jcbfm.2015.32. Epub 2015 Mar 11.
- Orr CF, Rowe DB, Halliday GM. An inflammatory review of Parkinson's disease. Prog Neurobiol. 2002 Dec;68(5):325-40. doi: 10.1016/s0301-0082(02)00127-2.
- Nagatsu T, Mogi M, Ichinose H, Togari A. Cytokines in Parkinson's disease. J Neural Transm Suppl. 2000;(58):143-51.
- Stypula G, Kunert-Radek J, Stepien H, Zylinska K, Pawlikowski M. Evaluation of interleukins, ACTH, cortisol and prolactin concentrations in the blood of patients with parkinson's disease. Neuroimmunomodulation. 1996 Mar-Jun;3(2-3):131-4. doi: 10.1159/000097237.
- Joyce N, Annett G, Wirthlin L, Olson S, Bauer G, Nolta JA. Mesenchymal stem cells for the treatment of neurodegenerative disease. Regen Med. 2010 Nov;5(6):933-46. doi: 10.2217/rme.10.72.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
November 9, 2020
Primary Completion (Actual)
July 30, 2023
Study Completion (Actual)
July 30, 2023
Study Registration Dates
First Submitted
July 16, 2020
First Submitted That Met QC Criteria
August 6, 2020
First Posted (Actual)
August 10, 2020
Study Record Updates
Last Update Posted (Estimated)
December 5, 2023
Last Update Submitted That Met QC Criteria
November 28, 2023
Last Verified
November 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- HSC-MS-20-0150
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Parkinson's Disease
-
Ohio State UniversityCompletedParkinson's Disease | Parkinson Disease | Idiopathic Parkinson Disease | Idiopathic Parkinson's Disease | Parkinson Disease, Idiopathic | Parkinson's Disease, IdiopathicUnited States
-
Assistance Publique - Hôpitaux de ParisFrance Parkinson AssociationUnknownHealthy Controls | Parkinson's Disease With LRRK2 Mutation | Parkinson's Disease Without LRRK2 MutationFrance
-
Merck Sharp & Dohme LLCCompletedParkinson Disease | Idiopathic Parkinson Disease | Idiopathic Parkinson's Disease
-
Universidade Federal de PernambucoCompletedParkinson's Disease.Brazil
-
University Hospital, GrenobleCompletedParkinson's Disease (Disorder)France
-
Neurocrine BiosciencesVoyager TherapeuticsCompletedBrain Diseases | Central Nervous System Diseases | Nervous System Diseases | Parkinson's Disease | Parkinsonian Disorders | Movement Disorders | Neurodegenerative Diseases | Idiopathic Parkinson's Disease | Basal Ganglia DiseaseUnited States
-
Second Affiliated Hospital of Soochow UniversityShanghai Regenelead Therapies Co., Ltd.RecruitingAdvanced Parkinson's DiseaseChina
-
AbbVieRecruitingParkinson's Disease (PD)Germany, Denmark, Spain
-
Beijing Tiantan HospitalRecruitingPD - Parkinson's DiseaseChina
-
Hubert FernandezRecruitingParkinson's Disease, IdiopathicUnited States
Clinical Trials on MSC+placebo
-
Longeveron Inc.bioRASI, LLCCompleted
-
Sixth Affiliated Hospital, Sun Yat-sen UniversityUnknownFistula | Crohn's Disease
-
Sorrento Therapeutics, Inc.Withdrawn
-
Sorrento Therapeutics, Inc.Withdrawn
-
Andalusian Initiative for Advanced Therapies -...Iniciativa Andaluza en Terapias AvanzadasCompletedDiscordant Immunological Response in HIV Infected SubjectsSpain
-
Brainstorm-Cell TherapeuticsCompletedAmyotrophic Lateral Sclerosis (ALS)United States
-
The University of QueenslandIsopogen; Cell and Tissue TherapiesCompletedChronic Lung Allograft Dysfunction (CLAD)Australia
-
Banc de Sang i TeixitsCompletedCOVID-19 | SARS-CoV 2 | Adult Respiratory Distress SyndromeSpain